Download

Full Text

• Löwenberg B: Treatment of the elderly patient with acute myeloid leukemia, in Löwenberg B (ed): Acute Myelogenous Leukemia and Myelodysplasia (vol 9). London, United Kingdom, Saunders, 1996, pp 147-159
• Liu Yin JA: Acute myeloid leukaemia in the elderly: Biology and treatment. Br J Haematol 83:1-6, 1993
• Löwenberg B, Zittoun R, Kerkhofs H, et al: On the value of intensive remission-induction chemotherapy in elderly patients of 65 + years with acute myeloid leukemia: A randomized phase III study of the EORTC Leukemia Group. J Clin Oncol 1:1268-1274, 1989
• Keating MJ, McCredie KB, Benjamin RS, et al: Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidizone and cytosine arabinoside, vincristine and prednisone (ROAP). Blood 58:584-590, 1981
• Kahn SB, Begg CB, Mazza JJ, et al: Full dose versus attenuated dose daunomycin, cytosine arabinoside and 6-thio-guanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 2:865-870, 1984
• Liu Yin JA, Johnson PRE, Davies JM, et al: Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukemia. Br J Haematol 79:415-420, 1991
• Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
• Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683, 1995
• Rowe JM, Andersen JW, Mazza JJ, et al: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E 1490). Blood 86:457-462, 1995
• Arlin Z, Case DC, Moore J, et al: Randomised multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177-183, 1990
• Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
• Housset M, Daniel MT, Degos L: Small doses of Ara-C in the treatment of acute myeloid leukemia: Differentiation of myeloid leukemia cells. Br J Haematol 51:125-129, 1982
• Winter JN, Variakojis D, Gaynor ER, et al: Low dose cytosine arabinoside therapy in the myelodysplastic syndromes and acute leukemia. Cancer 56:443-449, 1985
• Baccarini M, Zaccaria A, Bandini G, et al: Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. Leuk Res 7:539-545, 1983
• Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British group. Ann Intern Med 103:620-625, 1985
• Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 78:325-329, 1991
• Mitelman F (ed): Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1991
• Keating MJ, Smith TL, Kantarjian H, et al: Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 2:403-412, 1988
• Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263-270, 1989
• Dastugue N, Payen C, Lafage-Pochitaloff M, et al: Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia 9:1491-1498, 1995
• Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials: Methods and Practice. Oxford, UK, Oxford University Press, 1992
• Gardner MJ, Altman DG (eds): Statistics with confidence-Confidence intervals and statistical guidelines. Br Med J 1989
• Löwenberg B, Suciu S, Archimbaud E, et al: Use of recombinant granulocyte-macrophage colony-stimulating-factor (GM-CSF) during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer (EORTC-LC6) and the Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON). Blood 90:2952-2961, 1997
• Yates J, Glidewell O, Wiernik P, et al: Cytosine arabinoside with daunomycin or Adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 60:454-463, 1982
• Baudard M, Marie JP, Cadiou M, et al: Acute myelogenous leukaemia in the elderly: Retrospective study of 235 consecutive patients. Br J Haematol 86:82-91, 1994